Ms. Rachel Yu has served as our director since December 2023 and Chief Financial Officer since June 2024. Ms. Yu is a partner at Oceanpine Capital’s healthcare practice since May 2021, where she is responsible for formulating the overall investment strategies in the healthcare sector and taking day-to-day principal leadership responsibility in financial and operational management of financial team, investment team and portfolio companies. 

Prior to that, she was a partner at China Renaissance Group, where she worked from 2014 to 2021 and took the principal responsibility in deal sourcing, and conducting due diligence on investment targets, including financial and operational data, financial models and valuation and compliance. From 2012 to 2014, Ms. Yu served as vice president/head of China healthcare research at Gerson Lehman Group. Prior to that, Ms. Yu worked as an equity analyst at Maxim Group, Rodman & Renshaw, and Deutsche Bank Securities. 

Ms. Yu received her MBA from the University of Chicago Booth School of Business (2008-2010), her MSc in Pharmacology from The University of Missouri School of Medicine (2000-2002), and her BSc in Pharmacy from Guangdong Pharmaceutical University (1995-1999).